Company intelligence / Profile preview

Curative Enzymes

Ownership: Private
Development stage: Other

Overview

Curative Enzymes is a biotechnology company focused on the development of next-generation enzyme therapies for metabolic and inflammatory diseases. The company's primary focus is on engineering improved versions of therapeutic enzymes to address limitations in current treatments, such as immunogenicity and short half-life. Its lead research efforts involve recombinant urate oxidase variants intended for the treatment of chronic refractory gout and hyperuricemia. By utilizing advanced protein engineering, Curative Enzymes aims to provide more durable and less immunogenic options for patients with metabolic disorders.

Therapeutic areas: RheumatologyMetabolic Disorders
Modalities: Enzyme replacement therapyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Curative Enzymes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curative Enzymes.

Explore the full profile